Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9196637 | 1.00 | SLC1A3 (0.36) | SLC1A3SLC1A2SLC1A1ACHETP53 | |
| SCHEMBL6931998 | 1.00 | SLC1A3 (0.36) | SLC1A3SLC1A2SLC1A1ACHETP53 | |
| SCHEMBL14530119 | 0.80 | SLC1A3 (0.33) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL21916633 | 0.79 | ALDH1A1 (0.32) | ACHE | |
| SCHEMBL724845 | 0.78 | SLC1A3 (0.39) | SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL21881710 | 0.77 | ACHE (0.31) | ACHE | |
| SCHEMBL9162000 | 0.77 | ACHE (0.31) | ACHE | |
| SCHEMBL8600469 | 0.77 | ACHE (0.45) | ACHE | |
| SCHEMBL6289513 | 0.77 | ACHE (0.31) | SLC1A3SLC1A2SLC1A1ACHE | |
| SCHEMBL637417 | 0.76 | SLC1A3 (0.37) | SLC1A3SLC1A2SLC1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6256254-A | — | — | None | — | — | JP | disclosed |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| EP-2748158-A1 | RADIOLABELED COMPOUNDS AND THEIR USE AS RADIOTRACERS FOR QUANTITATIVE IMAGING OF PHOSPHODIESTERASE (PDE10A) IN MAMMALS | Takeda Pharmaceutical Company Limited (JP) | 2014-07-02 | — | — | EP | disclosed |
| EP-2479161-B1 | A novel process for producing 1,1,1,3,3,3-hexafluoro-2-methoxypropane | DAIKIN IND LTD (JP) | 2014-01-08 | — | — | EP | disclosed |
| WO-2013027845-A1 | RADIOLABELED COMPOUNDS AND THEIR USE AS RADIOTRACERS FOR QUANTITATIVE IMAGING OF PHOSPHODIESTERASE (PDE10A) IN MAMMALS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |
| EP-2479161-A1 | A novel process for producing 1,1,1,3,3,3-hexafluoro-2-methoxypropane | Daikin Industries, Ltd. (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-7985877-B2 | Carboxylic acid compound, use thereof, and process for producing the same | DAIKIN INDUSTRIES, LTD. (JP) | 2011-07-26 | — | — | US | disclosed |
| US-7985877-B2 | Carboxylic acid compound, use thereof, and process for producing the same | DAIKIN INDUSTRIES, LTD. (JP) | 2011-07-26 | — | — | US | disclosed |
| US-20090156861-A1 | NOVEL CARBOXYLIC ACID COMPOUND, USE THEREOF, AND PROCESS FOR PRODUCING THE SAME | DAIKIN INDUSTRIES, LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156861-A1 | NOVEL CARBOXYLIC ACID COMPOUND, USE THEREOF, AND PROCESS FOR PRODUCING THE SAME | DAIKIN INDUSTRIES, LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-0592669-B1 | OPTICALLY ACTIVE TRIFLUOROLACTIC ACID DERIVATIVE AND LIQUID CRYSTAL COMPOSITION | CHISSO CORP (JP) | 1998-01-28 | — | — | EP | disclosed |
| US-5693868-A | REACTING 2,2'-BIS(TRIFLUOROMETHANESULFONYLOXY)-1,1-BINAPHTHYL WITH A PHOSPHINE OXIDE IN THE PRESENCE OF A TRANSITION METAL-PHOSPHINE COMPLEX | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1997-12-02 | — | — | US | disclosed |
| US-5665270-A | Optically active trifluorolactic acid derivative and liquid crystal composition | CHISSO CORPORATION (JP) | 1997-09-09 | — | — | US | disclosed |
| EP-0771812-A1 | Method for producing an optically active diphosphine | Takasago International Corporation (JP) | 1997-05-07 | — | — | EP | disclosed |
| EP-0347066-B1 | New enantiomers and their isolation | LUNDBECK & CO AS H (DK) | 1995-03-15 | — | — | EP | disclosed |
| JP-H06256254-A | PRODUCTION OF 2-ALKYLOXY-3,3,3-TRIFLUOROPROPIONIC ACID | JAPAN ENERGY CORP | 1994-09-13 | — | — | JP | disclosed |
| US-RE34712-E | Pharmaceutically useful (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroiso benzofuran-5-carbonitrile and non-toxic acid addition salts thereof | H. LUNDBECK A/S (DK) | 1994-08-30 | — | — | US | disclosed |
| EP-0592669-A1 | OPTICALLY ACTIVE TRIFLUOROLACTIC ACID DERIVATIVE AND LIQUID CRYSTAL COMPOSITION | CHISSO CORPORATION (JP) | 1994-04-20 | — | — | EP | disclosed |
| US-4943590-A | ANTIDEPRESSANTS, STEREOSPECIFIC SYNTHESIS | H. LUNDBECK A/S (DK) | 1990-07-24 | — | — | US | disclosed |
| EP-0347066-A1 | New enantiomers and their isolation | H. LUNDBECK A/S (DK) | 1989-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | SLC1A3 3451/4885SLC1A2 3521/4885SLC1A1 3319/4885 |
| US-20090156861-A1 | NOVEL CARBOXYLIC ACID COMPOUND, USE THEREOF, AND PROCESS FOR PRODUCING THE SAME | HAO2, FTO, HCAR2 | SLC1A3 509/4885SLC1A2 824/4885SLC1A1 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.